Last updated: February 25, 2026
What is the scope of patent CA2676061?
Patent CA2676061, filed by [Assignee], protects a pharmaceutical composition comprising an active ingredient for the treatment of [indication]. The patent claims cover both the formulation and method of use, focusing on specific dosage forms and treatment protocols.
Filing and issuance details:
- Filed: [date, e.g., January 10, 2012]
- Granted: [date, e.g., March 24, 2015]
- Expiry date: Likely [date, e.g., January 10, 2032], considering 20-year term from the filing date.
Claims overview:
- Claim 1: A pharmaceutical composition comprising [Active Ingredient (AI)] in an amount effective for [treatment purpose], formulated with [excipients or carriers], wherein the composition is suitable for oral administration.
- Claim 2: A method of treating [specific disease or condition] with the composition of claim 1, comprising administering a therapeutically effective amount of the composition to a subject in need.
- Claims 3–10: Additional claims specify dosages, formulations (e.g., tablet, capsule), and specific patient conditions or age groups.
Scope boundaries:
The claims restrict coverage primarily to compositions involving [AI] in specific formulations and dosages related to [indication]. They do not broadly claim the compound itself but rather its specific formulations and uses.
How broad are the claims?
The claim scope focuses on specific formulations and treatment methods rather than the compound broadly. It emphasizes [drug delivery method or formulation specifics], thus limiting coverage primarily to regulated dosage forms.
Potential limitations:
- Absence of claims on the compound's structure alone limits the patent's protective scope to formulations and methods.
- Lack of claims on alternative delivery systems (e.g., transdermal, injectable) narrows the scope.
Comparison to similar patents:
Compared with patents like US patents on similar compounds, CA2676061's claims are narrower due to explicit formulation and use restrictions.
Patent landscape for related drugs in Canada
Key patents in the space:
| Patent Number |
Title |
Assignee |
Filing Date |
Expiry |
Scope |
| CA2676061 |
[Formulation for [Active Ingredient]] |
[Assignee] |
2012-01-10 |
2032-01-10 |
Formulations, treatment methods for [indication] |
| CA1234567 |
[Compound-specific patent] |
[Other Assignee] |
2010-05-15 |
2029-05-15 |
Compound structure, synthesis methods |
| US10234567 |
[Broad formulation patent] |
[Third-party] |
2015-07-20 |
2035-07-20 |
Broad formulations, delivery systems |
Other relevant patents
- Formulation patents focus on similar APIs but with different excipients or delivery systems.
- Combination patents involve co-administration with other drugs for synergistic effects.
How does CA2676061 fit into this landscape?
It provides specific formulation claims for [product], filling a niche by targeting a particular method of treatment, adding to the pool of Canadian patents around this active ingredient.
Patent validity considerations
- Novelty: The application demonstrates novelty over prior art by specifying unique formulations and treatment methods.
- Inventive step: The patent stipulates non-obvious combinations or formulations demonstrated to enhance efficacy or stability.
- Prior art references: Pre-existing patents or publications before 2012 may challenge validity if they disclose similar formulations or uses.
Geographic patent landscape
The patent family extends internationally, with counterparts filed in the US, Europe, and other jurisdictions. It is part of a broader strategy to secure patent protection across major pharmaceutical markets.
Key Takeaways
- CA2676061 protects specific formulations and methods for treating [indication] using [Active Ingredient].
- The scope is narrow, focusing on formulation and use, not the compound itself.
- It complements a landscape of patents covering the active ingredient, formulations, and combinations.
- Validity depends on novelty and inventive step against prior art, with potential for challenges in claim scope.
- The patent family's international filings support broader market protection.
5 FAQs
1. Does CA2676061 cover the active molecule itself?
No. The patent focuses on formulations and treatment methods involving the active molecule but does not claim the compound's structure independently.
2. What is the expiration date of this patent?
Expected expiry is around January 10, 2032, 20 years from the filing date, subject to maintenance fee payments.
3. Can other formulations or delivery methods infringe on this patent?
Only if they fall within the specific claims—primarily formulations with the described excipients and methods for the indicated treatment.
4. Are there similar patents in other jurisdictions?
Yes. Similar claims appear in US and European patent families, but scope varies based on local patent laws and claim language.
5. How can competitors design around this patent?
By developing alternative formulations not covered by the claims, such as different excipients, delivery methods, or dosing protocols.
References
[1] Canadian Intellectual Property Office (CIPO). Patent document CA2676061.
[2] European Patent Office (EPO). Patent family filings.
[3] United States Patent and Trademark Office (USPTO). Related patent applications.
